MBX Biosciences, Inc. (NYSE:MBX) Shares Purchased by Woodline Partners LP

Woodline Partners LP boosted its position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 17.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 608,721 shares of the company's stock after buying an additional 89,046 shares during the period. Woodline Partners LP owned approximately 1.82% of MBX Biosciences worth $11,219,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in MBX. Driehaus Capital Management LLC grew its stake in MBX Biosciences by 61.2% in the 4th quarter. Driehaus Capital Management LLC now owns 1,581,760 shares of the company's stock worth $29,152,000 after acquiring an additional 600,438 shares in the last quarter. Geode Capital Management LLC grew its stake in MBX Biosciences by 1,093.2% in the fourth quarter. Geode Capital Management LLC now owns 265,703 shares of the company's stock worth $4,898,000 after purchasing an additional 243,434 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new position in MBX Biosciences during the 4th quarter worth $3,133,000. Charles Schwab Investment Management Inc. bought a new stake in MBX Biosciences during the 4th quarter valued at $1,720,000. Finally, Northern Trust Corp purchased a new stake in shares of MBX Biosciences in the 4th quarter worth $1,671,000.

Insiders Place Their Bets

In other MBX Biosciences news, Director Ora H. Pescovitz purchased 7,693 shares of the stock in a transaction that occurred on Tuesday, April 8th. The shares were purchased at an average cost of $5.89 per share, for a total transaction of $45,311.77. Following the completion of the transaction, the director now owns 24,329 shares of the company's stock, valued at $143,297.81. The trade was a 46.24% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 52.19% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on MBX shares. Guggenheim reiterated a "buy" rating and issued a $44.00 price target on shares of MBX Biosciences in a research note on Thursday, April 10th. Citizens Jmp started coverage on shares of MBX Biosciences in a report on Thursday, April 10th. They set an "outperform" rating and a $38.00 price objective on the stock. Finally, JMP Securities began coverage on shares of MBX Biosciences in a research report on Thursday, April 10th. They issued a "market outperform" rating and a $38.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $37.50.

MBX Biosciences Price Performance

NYSE:MBX traded down $0.36 during trading hours on Friday, hitting $12.15. 198,240 shares of the stock were exchanged, compared to its average volume of 252,439. The firm's fifty day moving average price is $8.93 and its 200 day moving average price is $12.82. MBX Biosciences, Inc. has a 52-week low of $4.81 and a 52-week high of $27.50.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.